Drug news
Oralair for grass allergy likely to get FDA approval-Stallergenes
An oral immunotherapy aimed at grass and pollen allergies has a benefit and safety profile that supports its approval, according to briefing documents posted on Monday by the FDA ahead of a meeting by outside experts to discuss the drug. Oralair ,a sublingual AIT (allergan immunotherapy) tablet, made by Stallergenes SA, would be the first such licensed therapy in the United States. It has been in use in Europe since 2008
.Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins